Nvidia, AMD to pay 15% of China chip sales revenue to US govt- FT
THE WOODLANDS, TX - Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company specializing in nervous system diseases with a current market capitalization of $4.31 million, announced plans to initiate a follow-on market expansion study phase (PoC 2) of its proof-of-concept trial. According to InvestingPro analysis, the company appears undervalued at its current price of $1.75 per share. The study aims to evaluate the safety and effectiveness of its technology for mitigating cancer pain, with a focus on cancers that affect visceral organs.
The company’s technology involves a catheter-based microchip sensing array designed to detect and differentiate neural signals, potentially offering a new approach to transvascular diagnosis and treatment of peripheral nervous system diseases. Although still investigational and not yet cleared for marketing in the United States, Autonomix is developing this technology primarily for pain treatment in pancreatic cancer patients.
Following positive results from the initial proof-of-concept phase (PoC 1) involving patients with severe pancreatic cancer pain, Autonomix is set to commence the PoC 2 phase in the second quarter of 2025. This phase will explore additional indications, potentially doubling the addressable market by including gall bladder, liver, and bile duct cancers. While the company maintains a healthy current ratio of 5.31, InvestingPro data reveals the company is quickly burning through cash, a critical factor for investors to monitor.
Brad Hauser, CEO of Autonomix, expressed enthusiasm for the PoC 1 phase outcomes, highlighting significant pain reduction, decreased opioid use, and improved quality of life in patients. The upcoming PoC 2 phase is expected to build on this success and expand the investigation to additional cancers.
The company’s platform technology is also anticipated to address various indications across cardiology, hypertension, and chronic pain management. Autonomix has established relationships with key opinion leaders and is gathering emerging preclinical evidence in these areas.
Investors and media interested in Autonomix’s advancements should note that the information provided is based on a press release statement from the company. Forward-looking statements regarding the timing and potential outcomes of the PoC 2 phase involve risks and uncertainties, and actual results may differ materially from those projected. With the stock down 96.72% over the past year and an overall financial health score rated as ’WEAK’ by InvestingPro, investors should conduct thorough due diligence. InvestingPro subscribers have access to 8 additional key insights and comprehensive financial metrics to better evaluate investment opportunities.
In other recent news, Autonomix Medical, Inc. has successfully completed the initial phase of its proof-of-concept trial, demonstrating significant pain relief for patients with late-stage pancreatic cancer. The study, which involved 20 patients, showed a marked reduction in pain scores and a decrease in opioid use, with 73% of patients remaining opioid-free at the 4-6 week follow-up. Following these promising results, Autonomix plans to expand its trial to include other visceral cancers and earlier-stage pancreatic cancer patients. Additionally, Autonomix has secured a new patent from the European Patent Office, broadening its patent portfolio to over 80 issued patents. This patent covers methods and systems for nerve and receptor monitoring, which could have applications in treating conditions related to peripheral nerve bundles. Looking ahead, Autonomix aims to begin U.S. clinical trials in 2025 for FDA approval of its Sensing and RF Ablation System. The company has also integrated the Apex 6 Radiofrequency Generator into its system, a move that aligns with its strategy to expedite development and reduce risks. Autonomix’s CEO, Brad Hauser, expressed optimism about the technology’s potential to improve quality of life for pancreatic cancer patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.